pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Vocabria
drug
save

cabotegravir sodium

Marketedupdated 3mo ago
by ViiV Healthcare Company
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • company$GSKGSK plc2 co-mentions · 2 sources
  • company$GLAXFGSK plc2 co-mentions · 2 sources
  • tagInfectious Disease2 co-mentions · 2 sources
  • drugcabotegravir LA2 co-mentions · 2 sources

all catalysts(2)

drug expiry · 1
Apr 28, 2026
drug expiry
$GSK50.16+1.29%
4mo ago
GSK plc — cabotegravir sodium (Drug Expiry (US))
cabotegravir sodium
→
patent expiry · 1
Apr 28, 2026
patent expiry
$GSK50.16+1.29%
4mo ago
GSK plc — cabotegravir sodium (Constraining Patent Expiry (US))
cabotegravir sodium
→

Trials studying cabotegravir sodium

  • phase1Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participantscompletedn=138

Patent cliff

source: FDA Orange Book
first barrier falls
Feb 4, 2031
~4.5 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

  • Feb 4, 2031compositionUS 84101034.5y
  • Apr 28, 2026compositionUS 10927129

FDA exclusivities (1)

  • Jan 21, 2026NCENew Chemical Entity (5y)

News(0)

no news has mentioned this drug yet

brand
Vocabria
generic
cabotegravir sodium
indication
Human Immunodeficiency Virus (HIV) Infections (AIDS)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?